STOCK TITAN
  1. Home
  2. Sec-filings
  3. IOVA
  4. [SCHEDULE 13G/A] Iovance Biotherapeutics, Inc. SEC Filing

[SCHEDULE 13G/A] Iovance Biotherapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock IOVA logo
Iovance Biotherp

NASDAQ:IOVA

IOVA Rankings

#3380 Ranked by Market Cap
N/A Ranked by Dividends

IOVA Latest News

Jul 18, 2025
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jul 15, 2025
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
Jul 14, 2025
Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma
Jul 10, 2025
Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy
Jun 23, 2025
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

IOVA Latest SEC Filings

Jul 15, 2025
[8-K] Iovance Biotherapeutics, Inc. Reports Material Event
Jul 10, 2025
[Form 3] Iovance Biotherapeutics, Inc. Initial Statement of Beneficial Ownership
Jul 3, 2025
[8-K] Iovance Biotherapeutics, Inc. Reports Material Event

IOVA Stock Data

644.49M
295.51M
0.62%
84.02%
18.17%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN CARLOS